Olanzapine and aripiprazole combination Review article
Article Sidebar
Published:
Mar 31, 2016
Keywords:
olanzapine, aripiprazole, combination
Main Article Content
Abstract
The pace of innovation in a class of psychotropic drugs has slowed down over past years. Looking for some new therapeutic options the polytherapy is more and more popular. The article outlines benefits of the olanzapine and aripiprazole combination. This combination offers the better metabolic tolerance and potentially higher clinical effectiveness.
Article Details
Issue
Section
Articles
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Copyright: © Medical Education sp. z o.o. License allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)
References
1. Galling B, Roldán A, Rietschel L et al. Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials. Expert Opin on Drug Saf 2016; 15(5): 591-612.
2. Baandrup L, Gasse C, Jensen VD et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010; 71(2): 103-108.
3. Tiihonen J, Suokas JT, Suvisaari JM et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012; 69(5): 476-483.
4. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2014; 17(7): 1083-1093.
5. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89(1-3): 91-100.
6. Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr Res 2014; 152(1): 246-254.
7. Mir A, Shivakumar K, Williamson RJ et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008; 22(3): 244-253.
8. Schönfelder S, Schirmbeck F, Waltereit R et al. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clin Neuropharmacol 2011; 34(6): 256-257.
9. Mayabhate MM, Badar VA, Waradkar P, Somani A. Cognitive and psychomotor effects of adjunctive aripiprazole or paliperidone in patients of schizophrenia receiving olanzapine: a double blind placebo controlled clinical study. International Journal of Basic & Clinical Pharmacology 2014; 3(1): 130-138.
10. Fleischhacker WW, Heikkinen ME, Olié JP et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical \efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13(8): 1115-1125.
11. Chang JS, Ahn YM, Park HJ et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69(5): 720-731.
12. Wigand ME, Hertle C, Bechter K. Kombinationstherapie Aripiprazol plus Olanzapin – eine Option bei therapieresistenten Symptomen schizophrener Psychosen? (Combination therapy olanzapine plus aripiprazole – an option for the treatment of therapy-resistant symptoms of schizophrenia?) Psychopharmakotherapie 2015; 22: 136-147.
13. Andersen SE, Johansson M, Manniche C. The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients. Basic Clin Pharmacol Toxicol 2008; 103(1): 75-81.
14. Gallego JA, Bonetti J, Zhang J et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta- regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138(1): 18-28.
15. Choi HJ, Jung SH, Kang MH et al. Antipsychotics prescribing patterns of patients with schizophrenia admitted to Korean General Hospital Psychiatric Unit: 2001 to 2008. Clin Psychopharmacol Neurosci 2011; 9(1): 17-22.
16. Gaviria AM, Franco JG, Aguado V et al. A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish Province of Tarragona. PLoS One 2015; 10(10): e0139403. http://doi.org/10.1371/journal.pone.0139403.
17. Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; 3. http://doi.org/10.1002/14651858.
18. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006; 2(4): 427-443.
19. Snigdha S, Thumbi C, Reynolds GP, Neill JC. Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol 2008; 22(5): 567-571.
20. Skrede S, Fernø J, Vázquez MJ et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 2012; 15(2): 163-179.
21. Assié MB, Carilla-Durand E, Bardin L et al. The antipsychotics clozapine and olanzapine increase plasma glucose and corti-costerone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur J Pharmacol 2008; 592(1-3): 160-166.
22. Panariello F, De Luca V, de Bartolomeis A. Weight gain, schizophrenia and antipsychotics: new findings from Aanimal model and pharmacogenomic studies. Schizophrenia Research and Treatment 2011, ID 459284. http://doi.org/10.1155/2011/459284.
23. Tournier BB, Steimer T, Millet P et al. Innately low D2 receptor availability is associated with high novelty-seeking and enhanced behavioural sensitization to amphetamine. Int J Neuropsychopharmacol 2013; 16(8): 1819-1834.
24. Bäckström P, Etelälahti TJ, Hyytiä P. Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole. Addict Biol 2011; 16(1): 55-63.
25. Fan X, Borba CP, Copeland PM et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013; 127(3): 217-226.
26. Henderson DC, Fan X, Copeland PM et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009; 29(2): 165-169.
27. Chen JH, Wu YF, Liao XZ. The treatment efficacy of olanzapine combined with aripiprazole in female first-episode schizophrenia (in Chinese). Guide China Med. 2012; 10: 145-146.
28. Li WJ, Liu HX. A control study of aripiprazole combined with low dose olanzapine in the treatment of schizophrenia (in Chinese). J Clin Psychiatry 2013; 23(1): 72.
29. Duggal HS. Aripiprazole–olanzapine combination for treatment of schizophrenia. Can J Psychiatry 2004; 49(2): 151.
30. Cobo Gómez JV, Fuste G, Coronas R et al. Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients. Curr Drug Saf 2008; 3(3): 210-215.
31. Ginsberg DL. Add-on aripiprazole to treat olanzapine-induced metabolic syndrome. Primary Psychiatry 2007. Online.
32. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100(1): 4-22.
33. de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs 2015; 29: 773-799.
34. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197(4): 266-271.
35. Nguyen CT, Rosen JA, Bota RG. Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities. Prim Care Companion CNS Disord 2012; 14(5). http://doi.org/10.4088/PCC.12m01386.
36. Carli M, Calcagno E, Mainolfi P et al. Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology (Berl) 2011; 214(3): 639-652.
2. Baandrup L, Gasse C, Jensen VD et al. Antipsychotic polypharmacy and risk of death from natural causes in patients with schizophrenia: a population-based nested case-control study. J Clin Psychiatry 2010; 71(2): 103-108.
3. Tiihonen J, Suokas JT, Suvisaari JM et al. Polypharmacy with antipsychotics, antidepressants, or benzodiazepines and mortality in schizophrenia. Arch Gen Psychiatry 2012; 69(5): 476-483.
4. Fleischhacker WW, Uchida H. Critical review of antipsychotic polypharmacy in the treatment of schizophrenia. Int J Neuropsychopharmacol 2014; 17(7): 1083-1093.
5. Correll CU, Frederickson AM, Kane JM, Manu P. Does antipsychotic polypharmacy increase the risk for metabolic syndrome? Schizophr Res 2007; 89(1-3): 91-100.
6. Katona L, Czobor P, Bitter I. Real-world effectiveness of antipsychotic monotherapy vs. polypharmacy in schizophrenia: to switch or to combine? A nationwide study in Hungary. Schizophr Res 2014; 152(1): 246-254.
7. Mir A, Shivakumar K, Williamson RJ et al. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol 2008; 22(3): 244-253.
8. Schönfelder S, Schirmbeck F, Waltereit R et al. Aripiprazole improves olanzapine-associated obsessive compulsive symptoms in schizophrenia. Clin Neuropharmacol 2011; 34(6): 256-257.
9. Mayabhate MM, Badar VA, Waradkar P, Somani A. Cognitive and psychomotor effects of adjunctive aripiprazole or paliperidone in patients of schizophrenia receiving olanzapine: a double blind placebo controlled clinical study. International Journal of Basic & Clinical Pharmacology 2014; 3(1): 130-138.
10. Fleischhacker WW, Heikkinen ME, Olié JP et al. Effects of adjunctive treatment with aripiprazole on body weight and clinical \efficacy in schizophrenia patients treated with clozapine: a randomized, double-blind, placebo-controlled trial. Int J Neuropsychopharmacol 2010; 13(8): 1115-1125.
11. Chang JS, Ahn YM, Park HJ et al. Aripiprazole augmentation in clozapine-treated patients with refractory schizophrenia: an 8-week, randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 2008; 69(5): 720-731.
12. Wigand ME, Hertle C, Bechter K. Kombinationstherapie Aripiprazol plus Olanzapin – eine Option bei therapieresistenten Symptomen schizophrener Psychosen? (Combination therapy olanzapine plus aripiprazole – an option for the treatment of therapy-resistant symptoms of schizophrenia?) Psychopharmakotherapie 2015; 22: 136-147.
13. Andersen SE, Johansson M, Manniche C. The prescribing pattern of a new antipsychotic: a descriptive study of aripiprazole for psychiatric in-patients. Basic Clin Pharmacol Toxicol 2008; 103(1): 75-81.
14. Gallego JA, Bonetti J, Zhang J et al. Prevalence and correlates of antipsychotic polypharmacy: a systematic review and meta- regression of global and regional trends from the 1970s to 2009. Schizophr Res 2012; 138(1): 18-28.
15. Choi HJ, Jung SH, Kang MH et al. Antipsychotics prescribing patterns of patients with schizophrenia admitted to Korean General Hospital Psychiatric Unit: 2001 to 2008. Clin Psychopharmacol Neurosci 2011; 9(1): 17-22.
16. Gaviria AM, Franco JG, Aguado V et al. A non-interventional naturalistic study of the prescription patterns of antipsychotics in patients with schizophrenia from the Spanish Province of Tarragona. PLoS One 2015; 10(10): e0139403. http://doi.org/10.1371/journal.pone.0139403.
17. Komossa K, Rummel-Kluge C, Hunger H et al. Olanzapine versus other atypical antipsychotics for schizophrenia. Cochrane Database Syst Rev 2010; 3. http://doi.org/10.1002/14651858.
18. Citrome L. A review of aripiprazole in the treatment of patients with schizophrenia or bipolar I disorder. Neuropsychiatr Dis Treat 2006; 2(4): 427-443.
19. Snigdha S, Thumbi C, Reynolds GP, Neill JC. Ziprasidone and aripiprazole attenuate olanzapine-induced hyperphagia in rats. J Psychopharmacol 2008; 22(5): 567-571.
20. Skrede S, Fernø J, Vázquez MJ et al. Olanzapine, but not aripiprazole, weight-independently elevates serum triglycerides and activates lipogenic gene expression in female rats. Int J Neuropsychopharmacol 2012; 15(2): 163-179.
21. Assié MB, Carilla-Durand E, Bardin L et al. The antipsychotics clozapine and olanzapine increase plasma glucose and corti-costerone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox and F15063. Eur J Pharmacol 2008; 592(1-3): 160-166.
22. Panariello F, De Luca V, de Bartolomeis A. Weight gain, schizophrenia and antipsychotics: new findings from Aanimal model and pharmacogenomic studies. Schizophrenia Research and Treatment 2011, ID 459284. http://doi.org/10.1155/2011/459284.
23. Tournier BB, Steimer T, Millet P et al. Innately low D2 receptor availability is associated with high novelty-seeking and enhanced behavioural sensitization to amphetamine. Int J Neuropsychopharmacol 2013; 16(8): 1819-1834.
24. Bäckström P, Etelälahti TJ, Hyytiä P. Attenuation of reinforcing and psychomotor stimulant effects of amphetamine by aripiprazole. Addict Biol 2011; 16(1): 55-63.
25. Fan X, Borba CP, Copeland PM et al. Metabolic effects of adjunctive aripiprazole in clozapine-treated patients with schizophrenia. Acta Psychiatr Scand 2013; 127(3): 217-226.
26. Henderson DC, Fan X, Copeland PM et al. Aripiprazole added to overweight and obese olanzapine-treated schizophrenia patients. J Clin Psychopharmacol 2009; 29(2): 165-169.
27. Chen JH, Wu YF, Liao XZ. The treatment efficacy of olanzapine combined with aripiprazole in female first-episode schizophrenia (in Chinese). Guide China Med. 2012; 10: 145-146.
28. Li WJ, Liu HX. A control study of aripiprazole combined with low dose olanzapine in the treatment of schizophrenia (in Chinese). J Clin Psychiatry 2013; 23(1): 72.
29. Duggal HS. Aripiprazole–olanzapine combination for treatment of schizophrenia. Can J Psychiatry 2004; 49(2): 151.
30. Cobo Gómez JV, Fuste G, Coronas R et al. Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients. Curr Drug Saf 2008; 3(3): 210-215.
31. Ginsberg DL. Add-on aripiprazole to treat olanzapine-induced metabolic syndrome. Primary Psychiatry 2007. Online.
32. Spina E, de Leon J. Metabolic drug interactions with newer antipsychotics: a comparative review. Basic Clin Pharmacol Toxicol 2007; 100(1): 4-22.
33. de Bartolomeis A, Tomasetti C, Iasevoli F. Update on the mechanism of action of aripiprazole: translational insights into antipsychotic strategies beyond dopamine receptor antagonism. CNS Drugs 2015; 29: 773-799.
34. Kessing LV, Thomsen AF, Mogensen UB, Andersen PK. Treatment with antipsychotics and the risk of diabetes in clinical practice. Br J Psychiatry 2010; 197(4): 266-271.
35. Nguyen CT, Rosen JA, Bota RG. Aripiprazole partial agonism at 5-HT2C: a comparison of weight gain associated with aripiprazole adjunctive to antidepressants with high versus low serotonergic activities. Prim Care Companion CNS Disord 2012; 14(5). http://doi.org/10.4088/PCC.12m01386.
36. Carli M, Calcagno E, Mainolfi P et al. Effects of aripiprazole, olanzapine, and haloperidol in a model of cognitive deficit of schizophrenia in rats: relationship with glutamate release in the medial prefrontal cortex. Psychopharmacology (Berl) 2011; 214(3): 639-652.